Correlation of serum S100B concentration with hospital stay in patients undergoing CABG.
S100B protein has been proposed to be a serum marker of cerebral injury in patients undergoing cardiac surgery. The question to be answered in the present study was whether an increase in serum S100B concentration after the surgery correlated with the length of hospital stay in patients undergoing coronary artery bypass grafting. To answer this question we measured serum S100B concentration preoperatively, at the end of the operation, and on day 1 and day 5 of the surgery in 32 patients undergoing coronary artery bypass grafting. The median (min; max) hospital stay was 7 days (5; 34), and serum S100B concentration was 0.075 mg/L (0.050;0. 095) preoperatively, 0.840 mg/L (0.390; 1.500) immediately after the operation, 0.180 mg/L (0.150;0. 280) on day 1 and 0.100 mg/L (0.080;0. 120) on day 5 of the operation. None of the patients had clinical signs of cerebral injury. Multivariate linear regression analysis indicated serum S100B concentration on day 1 (p = 0.0296) and day 5 (p = 0.0021) of the operation to correlate with the length of hospital stay independently of the type of operation (with or without the use of cardiopulmonary bypass) and patient clinical characteristics. Our data suggest that serum S100B concentration on day 1 and day 5 of the operation may have prognostic value in patients without clinical signs of cerebral injury. However, this pilot study should be extended to a larger group of patients to confirm this observation.